Skip to main navigation
Skip to search
Skip to main content
Aston Research Explorer Home
Help & FAQ
Link opens in a new tab
Search content at Aston Research Explorer
Home
Research units
Profiles
Research Outputs
Datasets
Student theses
Activities
Press/Media
Prizes
Equipment
Cholinesterase inhibitors for Parkinson's disease dementia
Ian Maidment
, Chris Fox
, Malaz Boustani
Applied Health Research Group
Aston Pharmacy School
College of Health and Life Sciences
University of Kent
Regenstrief Institute Inc
Research output
:
Contribution to journal
›
Article
›
peer-review
118
Link opens in a new tab
Citations (SciVal)
175
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cholinesterase inhibitors for Parkinson's disease dementia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acetylcholinesterase Inhibitors (AChEI)
100%
Parkinson's Disease Dementia
100%
Rivastigmine
100%
Placebo
44%
Adverse Events
33%
Health Economics
33%
Economic Factors
22%
Clinically Significant
22%
Tolerability
22%
Activities of Daily Living
22%
EmrE
22%
ADAS-Cog
22%
Randomized Double-blind Placebo-controlled Study
22%
Dementia
11%
Parkinson's Disease
11%
Patient Well-being
11%
Search Methods
11%
Patients with Parkinson's Disease
11%
Quality of Life
11%
Search Terms
11%
Nausea
11%
Quality of Life Assessment
11%
Pharmaceutical Companies
11%
Parkinsonian
11%
Inclusion Criteria
11%
Disease Symptoms
11%
Healthcare Database
11%
Selection Criteria
11%
Caregivers
11%
Relevant Database
11%
Exclusion Criteria
11%
Cognitive Improvement
11%
Cognitive Measures
11%
Cochrane Collaboration
11%
Cochrane
11%
Pragmatic Measures
11%
Tremor
11%
Ongoing Trials
11%
Parkinson
11%
Safety Self-efficacy
11%
Vomiting
11%
Economic Safety
11%
Movement Symptoms
11%
Noradrenergic Innervation
11%
Last Observation Carried Forward
11%
Cholinergic Modulation
11%
Patient Acceptance
11%
Adverse Health
11%
ADCS-ADL
11%
Activity Quality
11%
Treatment Acceptability
11%
Economic Data
11%
High Dropout Rate
11%
Neuropsychiatric Features
11%
Large Trials
11%
Cholinergic Innervation
11%
Residential Care Facilities
11%
Trial Safety
11%
Global Impression
11%
Carer Quality of Life
11%
Comprehensive Search
11%
Medicine and Dentistry
Parkinson's Disease
100%
Rivastigmine
100%
Acetylcholinesterase Inhibitor
100%
Placebo
44%
Adverse Event
33%
Placebo-Controlled Study
22%
Quality of Life Assessment
11%
Quality of Life
11%
Innervation
11%
Health Care
11%
Nausea
11%
Residential Care
11%
Cholinergic Activity
11%
Arm
11%
Exclusion Criterion
11%
Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Cholinesterase Inhibitor
100%
Rivastigmine
100%
Placebo
44%
Adverse Event
33%
Tolerability
22%
Cholinergic Receptor Stimulating Agent
22%
Placebo-Controlled Study
22%
Dopamine Receptor Stimulating Agent
11%
Nausea
11%
Neuroscience
Parkinson's Disease
100%
Acetylcholinesterase Inhibitor
100%
Rivastigmine
100%
Placebo
66%
Quality of Life
22%
Cholinergic
11%
Innervation
11%
Tremor
11%
Cholinergic Activity
11%
Dopaminergic
11%